Lonza Plans $200-Million Investment in China for APIs and Intermediates

April 13, 2006
Patricia Van Arnum

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

ePT--the Electronic Newsletter of Pharmaceutical Technology

The custom manufacturer Lonza Group (Basel, Switzerland) will invest $200 million in Nansha Guangzhou, China, for production of active pharmaceutical ingredients (APIs) and intermediates.

The custom manufacturer Lonza Group (Basel, Switzerland, www.lonza.com) will invest $200 million in Nansha Guangzhou, China, for the production of active pharmaceutical ingredients (APIs) and intermediates.

The investment plan will occur in phases over a 3–5-year period. Lonza's plan design includes building a multipurpose API and intermediates plant complex with large- and pilot-scale production capabilities. The company also recently opened a new R&D center for intermediates and APIs in Nansha.

Related Content:

PharmTech News